Hepatitis C - FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH
Medical News Today - Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment

Experimental HCV protease inhibitor to receive fast track approval
Aidsmap - An experimental oral protease inhibitor for the treatment of hepatitis C virus has been granted fast track designation by the United States' Food and Drug Administration (FDA), the organisation that approves medicines for use in the US. The

Increase ribavirin dose for better HCV treatment response in
Aidsmap - In order to improve response to hepatitis C virus (HCV) treatment, individuals coinfected with HIV and HCV should increase their dose of ribavirin ( Copegus / Rebetol / Virazole ), according to two presentations to the Second International Workshop

First-Time Generic Approvals: Copegus, Tegretol, Roxicodone
Medscape News - Jan. 24, 2006 The US Food and Drug Administration (FDA) approved in December 2005 first-time generic 200-mg formulations of ribavirin and carbamazepine tablets, and 15- and 30-mg formulations of oxycodone HCl tablets. First-time doses (ie, no